Health Alert:

See the latest Coronavirus Information including vaccinations, testing sites, visitation restrictions, and more.

Types of Myeloproliferative Neoplasms (MPN)

The type of myeloproliferative neoplasm is based on whether too many red blood cells, white blood cells, or platelets are being made.

  • Chronic myelogenous leukemia (CML), occurs when immature cells that would be red blood cells, white blood cells, or platelets overtake the bone marrow and blood.
  • Essential thrombocythemia, occurs when too many platelets are made in the bone marrow.
  • Myelofibrosis (also called primary or chronic idiopathic myelofibrosis), occurs when abnormal blood cells and scarring build up within the bone marrow.
  • Polycythemia vera, occurs when too many red blood cells are formed in the bone marrow.
  • Chronic myeloproliferative disorders sometimes can become acute leukemia, in which too many immature abnormal white blood cells are made. This is a rare event.

Other, less common, myeloproliferative disorders include:

  • Chronic eosinophilic leukemia
  • Chronic neutrophilic leukemia
  • Mastocytosis
  • Myeloproliferative/myelodysplastic syndromes
  • Neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB OR FGFR1 genes

Statistics for Myeloproliferative Neoplasms

The incidence for each type of MPN varies.

  • Chronic myelogenous leukemia affects approximately 1.75 people per 100,000 per year.
  • Essential thrombocythemia affects 2.3 people per 100,000 per year.*
  • Myelofibrosis affects up to 1 person per 100,000 per year.*
  • Polycythemia vera affects up to 2.6 people per 100,000 per year.*

Reference: Anderson and McMullan, Curr Hematol Malig Rep. 2014 Aug 17. [Epub ahead of print] Epidemiology of MPN: What Do We Know?

Personalized Diagnostics at Penn Medicine

Penn Medicine's Center for Personalized Diagnostics (CPD) is paving the way for a new era of genomic medicine.

The CPD offers the highest volume of genome testing in the region, with a large volume of clinical and research samples to date. In clinical cases, disease-associated mutations have been reported in 75% of patient tests revealing results with prognostic and therapeutic significance.

Learn more about Penn Medicine's Center for Personalized Diagnostics.